Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Lebbeke – page 45

2 122 clinical trials in Lebbeke, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Lebbeke at a glance
2 122
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

2 122 trials in Lebbeke

Open in trial search

Medulloblastoma

Recruiting

Study on Medulloblastoma Treatment in Children Aged 3-5 Using Carboplatin and Drug Combination

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Carboplatin
  • Sponsor:University Medical Center Hamburg-Eppendorf

Study of Tabelecleucel for Patients with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Transplant Treatment Failure

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Tabelecleucel
  • Sponsor:Pierre Fabre Medicament

Study to Test if Zelpultide Alfa Helps Prevent Lung Disease in High-Risk Premature Babies

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Recombinant Human Surfactant Protein-D
  • Sponsor:Airway Therapeutics Inc.

Study of Volrustomig and Drug Combination for Patients with Early-stage Resectable Non-small Cell Lung Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Study on Tabelecleucel for Patients with Epstein-Barr Virus-Associated Diseases

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Tabelecleucel
  • Sponsor:Pierre Fabre Medicament

Study of Adagrasib Alone and with Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Adagrasib
  • Sponsor:Mirati Therapeutics Inc.

Study on the Effectiveness of INM004 for Children with Hemolytic Uremic Syndrome Caused by Shiga Toxin-Producing E. coli

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:EQUINE SHIGA TOXIN 1/2 IMMUNE FAB2
  • Sponsor:Chemo Research S.L.

Study on the Safety and Effects of Givinostat in Young Children with Duchenne Muscular Dystrophy (Ages 2 to Less Than 6 Years)

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Givinostat
  • Sponsor:Italfarmaco S.p.A.

Long-Term Safety and Efficacy Study of Mexiletine Hydrochloride for Patients with Myotonic Dystrophy Type 1 and Type 2

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Mexiletine Hydrochloride
  • Sponsor:Lupin Atlantis Holdings S.A.

Study on VE303 for Preventing Recurrent C. difficile Infection in Patients

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bacilli, Cluster Xvii, Strain Relative Clostridium_Aq Innocuum, Live
  • Sponsor:Vedanta Biosciences Inc.

Study of Avapritinib for Adults with Systemic Mastocytosis Who Previously Participated in an Avapritinib Study

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Avapritinib
  • Sponsor:Blueprint Medicines Corp.

Study of Ruxolitinib and Venetoclax for Children with Relapsed or Refractory Leukemia or Lymphoma with IL-7R/JAK-STAT Pathway Mutations

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Ruxolitinib
  • Sponsor:Prinses Maxima Centrum voor Kinderoncologie B.V.

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Lebbeke

What the registry says about research in the country

01 Gastroenterology Research

Innovative clinical research focusing on proton pump inhibitor (PPI) medication management in patients with chronic digestive conditions.

  • Functional Dyspepsia Management
  • Heartburn Treatment Optimization
  • Reflux Control Strategies

This study explores alternative approaches to managing digestive disorders, comparing on-demand PPI use and alginate therapy with traditional stepped-down treatment methods.

02 Primary Care Innovation

Ground-breaking research in medication deprescribing strategies, aimed at optimizing long-term medication use in primary care settings.

  • Medication Optimization
  • Patient-Centered Care
  • Evidence-Based Deprescribing

The research evaluates three distinct approaches to reducing unnecessary long-term medication use while maintaining therapeutic effectiveness.

03 Therapeutic Strategy Research

Investigation into alternative treatment approaches for common digestive conditions, focusing on patient safety and optimal outcomes.

  • Comparative Treatment Analysis
  • Long-term Medication Management
  • Quality of Life Assessment

This clinical trial aims to establish evidence-based guidelines for medication reduction while maintaining symptom control.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.